bullish

Pharmaron Beijing Co Ltd-H

Pharmaron Beijing Co Ltd (3759.HK/300759.CH) 2022/2021Q1 Results- Expectations Coexist with Concerns

We analyzed Pharmaron's performance in 2021 & 2022Q1.Expectations coexist with concerns. Its outlook/valuation logic would improve greatly if it can make breakthrough in CMC services and CGT services.

Equity Bottom-Up
361 Views, 02 May 2022 09:01
SUMMARY(Sign Up to Access)
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
  • Unlimited Research Summaries
  • Personalised Alerts
  • Custom Watchlists
  • Company Data & News
  • Events & Webinars
or
Trusted by:
Bloomberg
Societe Generale
SGX
Sequoia
Interactive Broker
Refinitiv
Already have an account? Sign In Now
Full Insight
(Paid Plans Only)
Discussions
(Paid Plans Only)
WHAT’S TRENDING
Insights
  • Trending
  • Latest
Logo
Top Quartile
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
ChinaHealth CareEquity Bottom-UpThematic (Sector/Industry)
Price Chart(Sign Up to Access)
analytics-chart
  • H&H (1112): Difficult Period?
    07 May 2022
  • Health And Happiness (H&H) (1112.HK) - High Bankruptcy Risk Together with Gloomy Prospects
    06 May 2022
  • Pre-IPO Betters Medical Investment Holdings - The Industry, the Business and the Concerns
    05 May 2022
  • Pharmaron Beijing Co Ltd (3759.HK/300759.CH) 2022/2021Q1 Results- Expectations Coexist with Concerns
    02 May 2022
  • WuXi AppTec Co Ltd (2359.HK/603259.CH) 2022Q1 - Some Points Worth the Attention
    27 Apr 2022
  • Hangzhou Tigermed Consulting (3347.HK/300347.CH) - The Business Model May Not Be a Safe Play
    25 Apr 2022
  • The Impact of COVID-19 and Shanghai Lockdown on China Healthcare
    21 Apr 2022
  • Pharmaron Beijing Co Ltd (3759.HK) 2021Q3 - Still Takes Time to Challenge Wuxi AppTec
    28 Oct 2021
x